DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR CRIZOTINIB
➤ Get the DrugPatentWatch Daily Briefing
« Back to Dashboard
All Clinical Trials for Crizotinib
| Trial ID |
Title |
Status |
Sponsor |
Phase |
Start Date |
Summary |
| NCT00939770 ↗ |
Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma |
Active, not recruiting |
National Cancer Institute (NCI) |
Phase 1/Phase 2 |
2009-09-01 |
RATIONALE: Crizotinib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This phase I/II trial is studying the side effects and best dose of crizotinib and
to see how well it works in treating young patients with relapsed or refractory solid tumors
or anaplastic large cell lymphoma.
|
| NCT00939770 ↗ |
Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma |
Active, not recruiting |
Children's Oncology Group |
Phase 1/Phase 2 |
2009-09-01 |
RATIONALE: Crizotinib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This phase I/II trial is studying the side effects and best dose of crizotinib and
to see how well it works in treating young patients with relapsed or refractory solid tumors
or anaplastic large cell lymphoma.
|
| NCT01082380 ↗ |
Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers |
Completed |
Pfizer |
Phase 1 |
2010-03-01 |
The rationale for this study is to investigate the absorption, metabolism and excretion of
[14C]PF 02341066 and characterize plasma, fecal and urinary radioactivity, and identify any
metabolites, if possible, of [14C]PF 02341066 in humans.
|
| NCT01121588 ↗ |
An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK) |
Active, not recruiting |
Pfizer |
Phase 1 |
2011-03-01 |
This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with
tumors except non-small cell lung cancer that are positive for ALK.
|
| NCT01125904 ↗ |
A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult Volunteers |
Completed |
Pfizer |
Phase 1 |
2010-06-01 |
An oral-liquid, pediatric form of crizotinib designed for use by pediatric patients is being
tested for its' palatability in adults.
|
| >Trial ID |
>Title |
>Status |
>Phase |
>Start Date |
>Summary |
Clinical Trial Conditions for Crizotinib
Condition Name
| Condition Name for Crizotinib |
| Intervention |
Trials |
| Non-Small Cell Lung Cancer |
25 |
| Healthy |
10 |
| Carcinoma, Non-Small-Cell Lung |
8 |
| Lung Cancer |
7 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Condition MeSH
| Condition MeSH for Crizotinib |
| Intervention |
Trials |
| Carcinoma, Non-Small-Cell Lung |
64 |
| Lung Neoplasms |
54 |
| Lymphoma |
17 |
| Neoplasms |
17 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Locations for Crizotinib
Trials by Country
| Trials by Country for Crizotinib |
| Location |
Trials |
| United States |
624 |
| China |
80 |
| Italy |
78 |
| Japan |
63 |
| Spain |
50 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Trials by US State
| Trials by US State for Crizotinib |
| Location |
Trials |
| California |
30 |
| Texas |
30 |
| Massachusetts |
27 |
| Florida |
25 |
| Pennsylvania |
23 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Progress for Crizotinib
Clinical Trial Phase
| Clinical Trial Phase for Crizotinib |
| Clinical Trial Phase |
Trials |
| Phase 4 |
3 |
| Phase 3 |
17 |
| Phase 2/Phase 3 |
1 |
| [disabled in preview] |
73 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Status
| Clinical Trial Status for Crizotinib |
| Clinical Trial Phase |
Trials |
| Recruiting |
57 |
| Not yet recruiting |
36 |
| Active, not recruiting |
25 |
| [disabled in preview] |
16 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Sponsors for Crizotinib
Sponsor Name
| Sponsor Name for Crizotinib |
| Sponsor |
Trials |
| Pfizer |
50 |
| National Cancer Institute (NCI) |
15 |
| Hoffmann-La Roche |
9 |
| [disabled in preview] |
12 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Sponsor Type
| Sponsor Type for Crizotinib |
| Sponsor |
Trials |
| Other |
132 |
| Industry |
108 |
| NIH |
15 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
